Welcome to our dedicated page for PEAR news (Ticker: PEAR), a resource for investors and traders seeking the latest updates and insights on PEAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PEAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PEAR's position in the market.
Pear Therapeutics (NASDAQ: PEAR) announced the acquisition and licensing of two digital therapeutic assets for treating a spectrum of depression conditions. The new assets aim to enhance Pear's prescription digital therapeutics (PDT) pipeline by addressing mild to severe depression and treatment-resistant cases. Integration of these assets will require clinical evaluation and a potential pivotal trial for FDA submission. With over 19 million U.S. patients affected by depression, the company is strategically positioning itself in a significant market, which has grown due to heightened mental health issues during the COVID-19 pandemic.
Pear Therapeutics, Inc. (NASDAQ: PEAR) expands its digital therapeutic (PDT) initiative with Crossroads to include Kentucky, New Jersey, and Virginia, enhancing access for patients with substance use disorder (SUD) and opioid use disorder (OUD). This extension builds on previous implementations in Pennsylvania, signifying a collaborative effort to combat the addiction crisis. Pear's PDTs, reSET® and reSET-O®, aim to provide 24/7 cognitive behavioral therapy, potentially benefiting thousands of additional patients monthly. The shared commitment reflects both companies' dedication to innovative treatment options amid a rising addiction crisis.
Pear Therapeutics has successfully completed its business combination with Thimble Point Acquisition Corp, becoming publicly traded on Nasdaq under the ticker symbol PEAR starting December 6, 2021. The transaction generated approximately $175 million in gross proceeds, which will be used to enhance Pear's position as a leader in prescription digital therapeutics (PDTs). The company aims to further commercialize its FDA-authorized PDTs and expand payer adoption. Shareholder approval for the transaction was received on November 30, 2021.